XML 48 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
12 Months Ended
Nov. 30, 2012
Nov. 30, 2011
Nov. 30, 2012
Xenogenics Corporation [Member]
Oct. 14, 2010
Xenogenics Corporation [Member]
Nov. 30, 2012
Multicell Immunotherapeutics [Member]
Equity Method Investment, Ownership Percentage     95.30% 56.40% 67.00%
Convertible Debt, Fair Value Disclosures $ 56,026 $ 64,596      
Cash, FDIC Insured Amount $ 250,000        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,049,066,807 1,884,958,275